Stockreport

Cardiff Oncology Reports Fourth Quarter and Full Year 2023 Results and Provides Business Update

Cardiff Oncology, Inc.  (CRDF) 
PDF - First patient dosed in Phase 2 first-line trial in patients with RAS-mutated mCRC for new lead program with the support of FDA and clinical execution from Pfizer Ignit [Read more]